Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Debt (2016 - 2025)

Historic Total Debt for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $71.3 million.

  • Ocular Therapeutix's Total Debt rose 413.25% to $71.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $71.3 million, marking a year-over-year increase of 413.25%. This contributed to the annual value of $71.3 million for FY2025, which is 413.25% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Total Debt of $71.3 million as of Q4 2025, which was up 413.25% from $70.6 million recorded in Q3 2025.
  • Ocular Therapeutix's Total Debt's 5-year high stood at $71.3 million during Q4 2025, with a 5-year trough of $14.9 million in Q1 2021.
  • Its 5-year average for Total Debt is $46.0 million, with a median of $45.2 million in 2023.
  • As far as peak fluctuations go, Ocular Therapeutix's Total Debt plummeted by 3515.03% in 2021, and later surged by 18808.31% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Total Debt stood at $25.0 million in 2021, then increased by 1.03% to $25.3 million in 2022, then soared by 160.47% to $65.8 million in 2023, then rose by 4.13% to $68.5 million in 2024, then rose by 4.13% to $71.3 million in 2025.
  • Its last three reported values are $71.3 million in Q4 2025, $70.6 million for Q3 2025, and $69.9 million during Q2 2025.